Access the full text.
Sign up today, get DeepDyve free for 14 days.
Zongmin Zhou, A. Pyriochou, A. Kotanidou, Georgios Dalkas, Martin Eickels, G. Spyroulias, C. Roussos, A. Papapetropoulos (2008)
Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress.American journal of physiology. Heart and circulatory physiology, 295 4
Harald Lapp, Veselin Mitrovic, Norbert Franz, Hubertus Heuer, Michael Buerke, J. Wolfertz, Wolfgang Mueck, S. Unger, Georg Wensing, R. Frey (2009)
Cinaciguat (BAY 58–2667) Improves Cardiopulmonary Hemodynamics in Patients With Acute Decompensated Heart FailureCirculation, 119
J. Stasch, C. Alonso‐Alija, H. Apeler, K. Dembowsky, A. Feurer, T. Minuth, E. Perzborn, M. Schramm, A. Straub (2002)
Pharmacological actions of a novel NO‐independent guanylyl cyclase stimulator, BAY 41‐8543: in vitro studiesBritish Journal of Pharmacology, 135
P. Craven, F. Derubertis (1983)
Requirement for heme in the activation of purified guanylate cyclase by nitric oxide.Biochimica et biophysica acta, 745 3
T. Radovits, S. Korkmaz, Christiane Miesel-Gröschel, B. Seidel, J. Stasch, B. Merkely, M. Karck, G. Szabó (2011)
Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemia-reperfusion injury after cardiopulmonary bypass.European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 39 2
Yunde Zhao, P. Brandish, Marilena DiValentin, J. Schelvis, Gerald Babcock, M. Marletta (2000)
Inhibition of soluble guanylate cyclase by ODQ.Biochemistry, 39 35
N. Weissmann, Sascha Hackemack, B. Dahal, S. Pullamsetti, R. Savai, M. Mittal, Beate Fuchs, Thomas Medebach, Rio Dumitrascu, M. Eickels, H. Ghofrani, W. Seeger, F. Grimminger, R. Schermuly (2009)
The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice.American journal of physiology. Lung cellular and molecular physiology, 297 4
G. Boerrigter, L. Costello-Boerrigter, A. Cataliotti, H. Lapp, J. Stasch, J. Burnett (2007)
Targeting Heme-Oxidized Soluble Guanylate Cyclase in Experimental Heart FailureHypertension, 49
J. Edwards, L. Ignarro, A. Hyman, P. Kadowitz (1984)
Relaxation of intrapulmonary artery and vein by nitrogen oxide-containing vasodilators and cyclic GMP.The Journal of pharmacology and experimental therapeutics, 228 1
J. Stasch, K. Dembowsky, E. Perzborn, Elke Stahl, M. Schramm (2002)
Cardiovascular actions of a novel NO‐independent guanylyl cyclase stimulator, BAY 41‐8543: in vivo studiesBritish Journal of Pharmacology, 135
L. Ignarro, R. Byrns, G. Buga, K. Wood (1987)
Endothelium‐Derived Relaxing Factor From Pulmonary Artery and Vein Possesses Pharmacologic and Chemical Properties Identical to Those of Nitric Oxide RadicalCirculation Research, 61
B. Wedel, P. Humbert, C. Harteneck, J. Foerster, J. Malkewitz, E. Böhme, G. Schultz, D. Koesling (1994)
Mutation of His-105 in the beta 1 subunit yields a nitric oxide-insensitive form of soluble guanylyl cyclase.Proceedings of the National Academy of Sciences of the United States of America, 91 7
C. Boulton, E. Southam, J. Garthwaite (1995)
Nitric oxide-dependent long-term potentiation is blocked by a specific inhibitor of soluble guanylyl cyclaseNeuroscience, 69
Chih-Ming Tseng, M. Tabrizi-Fard, Ho-Leung Fung (2000)
Differential sensitivity among nitric oxide donors toward ODQ-mediated inhibition of vascular relaxation.The Journal of pharmacology and experimental therapeutics, 292 2
W. Arnold, C. Mittal, S. Katsuki, F. Murad (1977)
Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations.Proceedings of the National Academy of Sciences of the United States of America, 74 8
J. Stasch, Peter Schmidt, C. Alonso‐Alija, H. Apeler, K. Dembowsky, Michael Haerter, M. Heil, T. Minuth, E. Perzborn, U. Pleiss, M. Schramm, W. Schroeder, H. Schröder, Elke Stahl, W. Steinke, F. Wunder (2002)
NO‐ and haem‐independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principleBritish Journal of Pharmacology, 136
J. Stone, M. Marletta (1996)
Spectral and kinetic studies on the activation of soluble guanylate cyclase by nitric oxide.Biochemistry, 35 4
Yunde Zhao, P. Brandish, D. Ballou, M. Marletta (1999)
A molecular basis for nitric oxide sensing by soluble guanylate cyclase.Proceedings of the National Academy of Sciences of the United States of America, 96 26
K. Homer, S. Fiore, J. Wanstall (1999)
Inhibition by 1H‐[1,2,4]Oxadiazolo[4,3‐a]quinoxalin‐1‐one (ODQ) of Responses to Nitric Oxide‐donors in Rat Pulmonary Artery: Influence of the Mechanism of Nitric Oxide GenerationJournal of Pharmacy and Pharmacology, 51
Yutang Wang, Hanzhong Liu, Gavin Mckenzie, P. Witting, J. Stasch, Michael Hahn, Dechaboon Changsirivathanathamrong, Ben Wu, H. Ball, Shane Thomas, V. Kapoor, D. Celermajer, A. Mellor, J. Keaney, N. Hunt, R. Stocker (2010)
Kynurenine is an endothelium-derived relaxing factor produced during inflammationNature Medicine, 16
J. Stasch, Peter Schmidt, P. Nedvetsky, T. Nedvetskaya, A. S., S. Meurer, Martin Deile, A. Taye, A. Knorr, H. Lapp, H. Müller, Y. Turgay, Christiane Rothkegel, A. Tersteegen, B. Kemp-Harper, W. Müller-Esterl, H. Schmidt (2006)
Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels.The Journal of clinical investigation, 116 9
H. Schmidt, Peter Schmidt, J. Stasch (2009)
NO- and haem-independent soluble guanylate cyclase activators.Handbook of experimental pharmacology, 191
L. Ignarro, Jonathan Degnan, W. Baricos, P. Kadowitz, M. Wolin (1982)
Activation of purified guanylate cyclase by nitric oxide requires heme. Comparison of heme-deficient, heme-reconstituted and heme-containing forms of soluble enzyme from bovine lung.Biochimica et biophysica acta, 718 1
M. Chester, P. Tourneux, G. Seedorf, T. Grover, J. Gien, S. Abman (2009)
Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus.American journal of physiology. Lung cellular and molecular physiology, 297 2
W. Mueck, R. Frey (2010)
Population Pharmacokinetics and Pharmacodynamics of Cinaciguat, a Soluble Guanylate Cyclase Activator, in Patients with Acute Decompensated Heart FailureClinical Pharmacokinetics, 49
J. Stone, M. Marletta (1994)
Soluble guanylate cyclase from bovine lung: activation with nitric oxide and carbon monoxide and spectral characterization of the ferrous and ferric states.Biochemistry, 33 18
Adeleke Badejo, Vaughn Nossaman, Edward Pankey, M. Bhartiya, C. Kannadka, S. Murthy, B. Nossaman, P. Kadowitz (2010)
Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide.American journal of physiology. Heart and circulatory physiology, 299 4
A. Knorr, C. Hirth‐Dietrich, C. Alonso‐Alija, M. Härter, Michael Hahn, Yvonne Keim, F. Wunder, J. Stasch (2008)
Nitric Oxide-independent Activation of Soluble Guanylate Cyclase by BAY 60-2770 in Experimental Liver FibrosisArzneimittel-Forschung (Drug Research), 58
J. Braughler, C. Mittal, F. Murad (1979)
Effects of thiols, sugars, and proteins on nitric oxide activation of guanylate cyclase.The Journal of biological chemistry, 254 24
J. Garthwaite, E. Southam, C. Boulton, E. Nielsen, K. Schmidt, B. Mayer (1995)
Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one.Molecular pharmacology, 48 2
Abstract 4-({(4-Carboxybutyl)2-(5-fluoro-2-{4′-(trifluoromethyl)biphenyl-4-ylmethoxy}phenyl)ethylamino}methyl)benzoic acid (BAY 60–2770) is a nitric oxide (NO)-independent activator of soluble guanylyl cyclase (sGC) that increases the catalytic activity of the heme-oxidized or heme-free form of the enzyme. In this study, responses to intravenous injections of the sGC activator BAY 60–2770 were investigated under baseline and elevated tone conditions induced by the thromboxane mimic U-46619 when NO synthesis was inhibited by N ω -nitro- l -arginine methyl ester hydrochloride ( l -NAME), when sGC activity was inhibited by 1H-1,2,4-oxadizaolo4,3quinoxaline-1-one (ODQ), an agent that oxidizes sGC, and in animals with monocrotaline-induced pulmonary hypertension. The intravenous injections of BAY 60–2770 under baseline conditions caused small decreases in pulmonary arterial pressure, larger decreases in systemic arterial pressure, and no change or small increases in cardiac output. Under elevated tone conditions during infusion of U-46619, intravenous injections of BAY 60–2770 caused larger decreases in pulmonary arterial pressure, smaller decreases in systemic arterial pressure, and increases in cardiac output. Pulmonary vasodilator responses to BAY 60–2770 were enhanced by l -NAME or by ODQ in a dose that attenuated responses to the NO donor sodium nitroprusside. ODQ had no significant effect on baseline pressures and attenuated pulmonary and systemic vasodilator responses to the sGC stimulator BAY 41–8543 2-{1-2-(fluorophenyl)methyl-1H-pyrazolo3,4-bpyridin-3-yl}-5(4-morpholinyl)-4,6-pyrimidinediamine. BAY 60–2770 and sodium nitroprusside decreased pulmonary and systemic arterial pressures in monocrotaline-treated rats in a nonselective manner. The present data show that BAY 60–2770 has vasodilator activity in the pulmonary and systemic vascular beds that is enhanced by ODQ and NOS inhibition, suggesting that the heme-oxidized form of sGC can be activated in vivo in an NO-independent manner to promote vasodilation . These results show that BAY 60–2770 and sodium nitroprusside decreased pulmonary and systemic arterial pressures in monocrotaline-treated rats, suggesting that BAY 60–2770 does not have selective pulmonary vasodilator activity in animals with monocrotaline-induced pulmonary hypertension. guanylyl cyclase/activator/stimulator/inhibitor 4-({(4-carboxybutyl)2-(5-fluoro-2-{4′-(trifluoromethyl)biphenyl-4-ylmethoxy}phenyl)ethylamino}methyl)benzoic acid 2-{1-2-(fluorophenyl)methyl-1H-pyrazolo3,4-bpyridin-3-yl}-5(4-morpholinyl)-4,6-pyrimidinediamine nitric oxide/synthase/donor pulmonary hypertension pulmonary and systemic vascular beds U-46619 N ω -nitro- l -arginine methyl ester hydrochloride 1H-1,2,4-oxadizaolo4,3quinoxaline-1-one monocrotaline sodium nitroprusside Copyright © 2011 the American Physiological Society
AJP - Heart and Circulatory Physiology – The American Physiological Society
Published: Mar 1, 2011
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.